In this week's Homerun Slides, we conclude our 12-part series with pharmacologic approaches to treating chronic kidney disease in type 2.

Future directions and potential application of metabolite profiling in type 2 diabetes: metabolomics approaches have unmasked a variety of metabolic pathways influenced by T2DM or insulin resistance, moving the field of metabolic physiology beyond a “glucocentric” viewpoint of these conditions. However, a difficulty in interpretation is that the fasting concentration of a metabolite only reflects a single moment in time, and etiology or tissue origins of any metabolite differences across comparator groups requires further validation.

Study uses continuous glucose monitoring (CGM) systems to assess blood glucose levels during sleep.

A 62-year-old Asian-American female arrives at your office for a new patient appointment. Her current medications are metformin, pioglitazone, enalapril, lovastatin, alendronate, calcium supplements and vitamin D. Her A1C is on target at 6.9%, however you decide to replace her pioglitazone with a different antihyperglycemic medication. Why would you make this decision? A. Pioglitazone increases the risk of hypertriglyceridemia B. Pioglitazone increases the risk for cardiovascular events C. Pioglitazone increases the risk for fractures D. Pioglitazone increases the risk for hypoglycemia Follow the link to see the right answer.

Are you open to recommending an SGLT-2 inhibitor as a second drug for a patient with type 2 diabetes who is overweight and has not met their goal? Follow the link to see how you compare to your colleagues.

Pharmacy innovator Keith Campbell, B.Pharm, MBA, CDE, who sits on our board of advisors at Diabetes in Control, is one of the first pharmacists to become a certified diabetes educator and the inspiration for hundreds of other pharmacists and nurses who since followed in his footsteps, received the Lifetime Achievement Award on Friday, Oct. 20, 2017 at the Washington State University College of Pharmacy Crimson Gala.

In this week's Homerun Slides, liraglutide's effects on and action in diabetes, and therapeutic ways to treat chronic kidney disease in people with type 2.

Altered metabolites and their potential origins in type 2 diabetes and insulin resistance: In recent years, a large number of cross-sectional and prospective studies have revealed specific metabolites and pathways that are altered by, or predictive of, T2DM and insulin resistance.

New study finds that adults with type 2 diabetes and atherosclerotic cardiovascular disease have increased risk of mortality with a prior nonfatal cardiovascular (CV) event.

Large cohort suggests supplement increase beneficial in women of reproductive age.